Partnership addresses biopharmaceutical industry’s urgent need for improved in-process and QC testing tools for these rapidly evolving application fields
BOULDER, CO - 
(NewMediaWire) - June 5, 2024 - InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047) specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.
Since 2003, InDevR’s core focus has been to deliver innovative analytical tools for the vaccine industry. “Moving forward, our goal is to leverage that expertise to address the urgent need for improved analytical tools for cell and gene therapies and mRNA vaccine testing. Our partnership with Sino Biological, with their extraordinary breadth and depth of offerings and commitment to quality, will drive new product development and empower our customers to design their own multiplex assays with ease,” said Dr. Kathy Rowlen, CEO of InDevR.
Experts in recombinant protein production and antibody development, Sino Biological is equally enthusiastic about the collaboration. "We are thrilled to partner with InDevR to enhance the capabilities of their VaxArray Platform," Sino Biological Chief Business Officer Dr. Rob Burgess stated. "Our comprehensive range of quality reagents, combined with InDevR's cutting-edge analytical technology, promises to deliver superior solutions for in-process and quality control testing in the biopharmaceutical industry."
About InDevR
InDevR is a leader in innovative solutions for in-process, QC, and release testing of vaccines. Committed to enhancing the speed and accuracy of vaccine and other biological product characterization, InDevR’s products and services are trusted by leading pharmaceutical companies and research institutions around the globe.
About Sino Biological
Sino Biological is an international reagent supplier and contract research service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced with a stringent quality management system, and include unique bioreagents addressing areas such as cell therapy, stem cell, and infectious disease research. In addition, Sino Biological offers contract research production services for the custom development of full length, bioactive proteins and high-affinity antibodies, along with other services. To learn more about Sino Biological visit www.sinobiological.com, follow the company on LinkedIn or @SinoInc on Twitter.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on InDevR and Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which neither InDevR nor Sino Biological has control. InDevR and Sino Biological assume no obligation to update these forward-looking statements and do not intend to do so.
For media inquiries or partnership opportunities, please contact:
InDevr, Inc.
Craig Hoechstetter
Vice President, Sales & Marketing
csh@indevr.com
Sino Biological, Inc.
gmo@sinobiological.cn
